News | December 21, 2023
AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
New facility is part of Aptar Pharma’s global expansion program
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
There has been no loss or injury to human life
Subscribe To Our Newsletter & Stay Updated
